Intelligence Briefing · ~4 min read
Increased Competition in Opioid Pain Management Following Recent FDA Approvals
Pain Management · Opioid
Type
Strategic BriefingGenerated
Jul 23, 2026
Confidence
Moderate Confidence · 72%
Evidence
17 items
Sources
17
Key Takeaways
Leadership-ready summary — read in 4 minutes.
- Lannett's entry into the market may impact pricing and market share for existing opioid products, necessitating strategic adjustments from competitors. The strongest clinical anchor is Effect of Nociception Level Monitoring During Remimazolam-based Total Intravenous Anesthesia on Intraoperative Opioid Requirements and Postoperative Pain (ClinicalTrials.gov), sub-indication match (pain). In pain, 8 regulatory and 3 competitive items passed relevance filtering for existing opioid manufacturers.
- Monitor the market entry timelines and initial sales performance of newly approved generics, particularly Lannett's oxycodone and Upsher Smith's morphine sulfate.
- Watch for pricing strategies from both new entrants and existing competitors as they respond to the changing landscape.
Why It Matters
Strategic context for leadership and portfolio decision-making.
Lannett's entry into the market may impact pricing and market share for existing opioid products, necessitating strategic adjustments from competitors. The strongest clinical anchor is Effect of Nociception Level Monitoring During Remimazolam-based Total Intravenous Anesthesia on Intraoperative Opioid Requirements and Postoperative Pain (ClinicalTrials.gov), sub-indication match (pain). In pain, 8 regulatory and 3 competitive items passed relevance filtering for existing opioid manufacturers.
Supporting Evidence
Evidence-backed items from the Humanexa intelligence graph.
Hikma's ANDA090964 for Oxymorphone Hydrochloride Receives AP Status
Pain Management · Opioid
Source: Regulatory Approval
View evidenceFDA Approval of Oxycodone Hydrochloride ANDA203823 by Lannett Co Inc
Pain Management · Opioid
Source: Regulatory Approval
View evidenceFDA Approval Letter for Morphine Sulfate by Upsher Smith Labs
Pain Management · Opioid
Source: Regulatory Approval
View evidenceFDA Approval Update for Hydrocodone Bitartrate and Acetaminophen by SPECGX LLC
Pain Management · Opioid Combination
Source: Regulatory Approval
View evidenceFDA Approves ANEXSIA 5/325 Submission by SPECGX LLC
Pain Management · Combination Analgesics
Source: Regulatory Approval
View evidenceHikma's Tapentadol Hydrochloride ANDA205057 Receives AP Status
Pain Management · Opioid
Source: Regulatory Approval
View evidence
Related Intelligence
Deep links to signals, insights, companies, and assets in the Humanexa graph.
Signals
- Hikma's ANDA090964 for Oxymorphone Hydrochloride Receives AP Status
Pain Management · Opioid
- FDA Approval of Oxycodone Hydrochloride ANDA203823 by Lannett Co Inc
Pain Management · Opioid
- FDA Approval Letter for Morphine Sulfate by Upsher Smith Labs
Pain Management · Opioid
- FDA Approval Update for Hydrocodone Bitartrate and Acetaminophen by SPECGX LLC
Pain Management · Opioid Combination
- FDA Approves ANEXSIA 5/325 Submission by SPECGX LLC
Pain Management · Combination Analgesics
- Hikma's Tapentadol Hydrochloride ANDA205057 Receives AP Status
Pain Management · Opioid
- FDA Approval Letter for Tramadol Hydrochloride by Sun Pharma
Pain Management · Analgesic
- FDA Approves ANDA for Oxymorphone Hydrochloride by Hikma
Pain Management · Opioid
- FDA Approval Letter for Hydrocodone Bitartrate and Acetaminophen
Pain Management · Opioid Combination
- FDA Grants Approval for Tramadol Hydrochloride ANDA209404 by Macleods
Pain Management · Opioid
- Hikma's Roxicet ANDA089351 Receives Abbreviated Approval from FDA
Pain Management · Opioid
- FDA Approval Letter for Hydrocodone Bitartrate and Acetaminophen
Pain Management · Opioid Combination
Insights
- Increased Competition in Opioid Pain Management Following Recent FDA Approvals
Pain Management · Opioid